Last updated: 15 Dec 2018




Papua New Guinea

Region: WPRO

Key information on co-financing

• Gross National Income per capita (2017): \$ 2,410

 Co-financing status (2019): Accelerated transition phase Country will start self-financing all its vaccines from 2021, except IPV.



Immunisation financing

| | | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---------------------------------------|----|--------------|--------------|---------------|--------------|-----------|--|
| Vaccines used in routine immunisation | | | | | | | |
| - Government expenditure | \$ | 1,673,079 \$ | 1,141,391 \$ | 1,253,329 \$ | 1,043,588 \$ | 315,811 | |
| - Total expenditure | \$ | 2,693,920 \$ | 3,180,000 \$ | 2,691,757 \$ | 2,552,462 \$ | 1,626,131 | |
| - Government as % of total | | 62% | 36% | 47% | 41% | 19% | |
| Routine immunisation | | | | | | | |
| - Government expenditure | \$ | 2,118,613 \$ | 3,292,234 \$ | 1,253,329 \$ | 1,049,974 \$ | 321,456 | |
| - Total expenditure | \$ | 6,365,102 \$ | 6,140,236 \$ | 10,870,722 \$ | 3,068,766 \$ | 2,828,621 | |
| - Government as % of total | | 33% | 54% | 12% | 34% | 11% | |


Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product:

0.02%

Source: WHO National Health Accounts, 2015

Expenditure on routine immunisation in 2017



Gavi supported vaccines

| Vaccines | Туре | Year(s) of Gavi support | Co-financing required |
|-----------------|----------|-------------------------|-----------------------|
| Tetra DTP-HepB | Routine | 2007-2008 | Yes |
| Pentavalent | Routine | 2009-present | Yes |
| PCV | Routine | 2013-present | Yes |
| Measles | Routine | 2015-present | No |
| IPV | Routine | 2015-present | No |
| Measles-Rubella | Campaign | 2015 | No |
| Measles-Rubella | Routine | 2016-present | Yes |


Co-financing payments

| | Tota | l amount paid by the country | Co-fina | ced vaccines | |
|------|------|------------------------------|---------|--------------|--|
| 2009 | \$ | 658,000 | Penta | _ | |
| 2010 | \$ | 516,000 | Penta | - | |
| 2011 | \$ | 473,000 | Penta | - | |
| 2012 | \$ | 607,000 | Penta | - | |
| 2013 | \$ | 261,000 | Penta | PCV | |
| 2014 | \$ | 542,000 | Penta | PCV | |
| 2015 | \$ | 950,000 | Penta | PCV | |
| 2016 | \$ | 917,000 | Penta | PCV | |
| 2017 | \$ | 1,357,000 | Penta | PCV | |
| 2018 | \$ | 1,622,000 | Penta | PCV | |

Co-financing obligations for 2019

| | Co-financing obligation (in US\$) | s Co-financing obligations (in doses) |
|----------------------|-----------------------------------|---------------------------------------|
| Pentavalent Total | \$ 212,50 \$ 212,5 0 | - , |

Co-financing projections for 2020 - 2024



| | 2020 | 2021 | 2022 | 2023 | 2024 |
|-------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Penta | \$ 657,911 | \$ 726,262 | \$ 737,562 | \$ 748,844 | \$ 760,065 |
| PCV | \$ 1,779,381 | \$ 2,157,722 | \$ 2,191,296 | \$ 2,224,813 | \$ 2,258,151 |
| Total | \$ 2,437,292 | \$ 2,883,984 | \$ 2,928,858 | \$ 2,973,657 | \$ 3,018,216 |

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.